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A cumulative number of approaches have been carried out to elucidate the pathogenesis of
Alzheimer’s disease (AD). Tangles formation has been identified as a major event involved
in the neurodegenerative process, due to the conversion of either soluble peptides or
oligomers into insoluble filaments. Most of recent studies share in common the observa-
tion that formation of tau oligomers and the subsequent pathological filaments arrays is a
critical step in AD etiopathogenesis. Oligomeric tau species appear to be toxic for neuronal
cells, and therefore appear as an appropriate target for the design of molecules that may
control morphological and functional alterations leading to cognitive impairment.Thus, cur-
rent therapeutic strategies are aimed at three major types of molecules: (1) inhibitors of
protein kinases and phosphatases that modify tau and that may control neuronal degener-
ation, (2) methylene blue, and (3) natural phytocomplexes and polyphenolics compounds
able to either inhibit the formation of tau filaments or disaggregate them. Only a few
polyphenolic molecules have emerged to prevent tau aggregation. In this context, fulvic
acid (FA), a humic substance, has potential protective activity cognitive impairment. In fact,
formation of paired helical filaments in vitro, is inhibited by FA affecting the length of fibrils
and their morphology.
Keywords: tau oligomers, PHFs, Alzheimer’s disease, tauopathies, diagnosis and treatment
INTRODUCTION
Tau protein, a member of the microtubule-associated protein
(MAPs) family, plays a fundamental role in the assembly and sta-
bilization of microtubules, as well as on axonal transport and
neurite outgrowth (1–3). In this context, tau protein plays an
important role in the maintenance of neuronal polarity and in
the stabilization of the morphology of differentiated neurons.
In developing neurons, tau activity is crucial for the morpho-
genesis of the growth cones and, it has been suggested to play
a key role in promoting axonal growth (4). Tau is encoded
by a single gene located on chromosome 17 (17q21), possess-
ing 16 exons in its primary transcript. Six different isoforms
are expressed by post transcriptional modifications (alternative
splicing) from the primary transcript. Mature protein length
is about 352 up to 441 amino acid residues, and a molecu-
lar weights of 45–65 kDa depending on the tau isoforms (5, 6).
The C-terminal region has a domain containing the microtubule-
binding repeats, which is critical for microtubule assembly (2),
whereas the affinity of tau for microtubules is finely regulated
by an orchestrated set of phosphorylations. The motif KXGS
is one of several different motifs located within these repeats
susceptible to be phosphorylated (7). In turn, tau is character-
ized as an hydrophilic cationic protein, unfolded under native
conditions, and with a low ordered secondary structure (8). In
addition to roles in stabilization of microtubules, tau plays a
major role in bridging the different cytoskeletal structures. Thus,
besides microtubules, tau interacts with actin and intermediate
filaments (2, 9).
Tau is located primarily in neurons, however, traces of this
protein have been found in certain non-neuronal cells. Under
pathological conditions, tau can be also expressed in glial cells
(10). It is also possible to find tau or it’s mRNA in several peripheral
tissues such as heart, liver, lung, skeletal muscle, among others (11–
13). Interestingly, tau variants have been also observed in human
platelets (3, 14, 15).
Tau phosphorylation plays an important role in regulating
its binding to microtubules and thereby regulating their stabil-
ity within neuronal cells. However, under pathological situations,
tau protein is abnormally phosphorylated or dephosphorylated in
specific residues, perhaps due to the activities of various protein
kinases and phosphatases (such as GSK-3β and Cdk-5, and PP1A
and PP2, respectively) (16, 17). This change in the phosphoryla-
tion state of tau can lead to irreversible changes in the dynamics
of microtubules, cellular dysfunction, ultimately triggering cell
death of the neuron (6, 18). Moreover, tau protein may have other
post-translational modifications, including: (i) glycosylations, (ii)
ubiquitinations, (iii) truncations, and (iv) nitrations (6).
Hyperphosphorylated tau protein is the main component of
abnormal protein aggregates found in the neurons of patients
with neurodegenerative brain disorders known as tauopathies.
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Those neurodegenerative diseases have in common the pres-
ence of intraneuronal aggregates of tau. These aggregates are
known as Neurofibrillary Tangles (NFTs) and are made up of
paired helical filaments (PHFs) and straight filaments mainly com-
posed of hyperphosphorylated tau. The formation of PHFs from
tau molecules may follow different steps and could involve tau
phosphorylations, followed by limited proteolysis and conforma-
tional changes in tau protein (19), and finally its polymerization
into aberrant polymers in neuronal cells. These neuronal dis-
orders include: Pick’s disease, corticobasal degeneration (CBD),
progressive supranuclear palsy (PSP), frontotemporal dementia
with Parkinsonism linked to chromosome 17 (DFTP-17) and
Alzheimer’s disease (AD). AD is considered the most prevalent
tauopathy worldwide (20). In AD, abnormal phosphorylations
occur and specifically tag certain amino acids of tau protein:
Ser202, Thr205, Ser235, and Ser404 (21). These post-translational
modifications are catalyzed by two main protein kinases: the Cdk-
5/p35 system and GSK-3β (6). In this paper, we focus on how tau
oligomers became the focus for the search for new drugs, and also
potential targets for accurate diagnosis of AD.
ARE TAU OLIGOMERS RESPONSIBLE FOR NEURONAL
DEGENERATION? TECHNICAL APPROACHES
Insoluble aggregates of the MAP tau characterize a number of
tauopathies. Although there is much evidence linking tau to neu-
rodegeneration, the precise mechanism of tau-mediated neuro-
toxicity remains to be elucidated. In fact, tau oligomers appear to
be the toxic form of tau in neurodegenerative disease. In agree-
ment with this hypothesis, the presence of immunoreactive tau
protein in neurons of AD brain tissue, previous to tangle forma-
tion, has been shown. Binder and coworkers have produced the
novel monoclonal antibody TOC1 that recognizes non-fibrillary
tau. This antibody is selective in terms of specifically labeling tau
dimers and oligomers, but does not label tau filaments. Time-
course analysis and antibody labeling indicates that oligomers
appear as an early event in AD pathogenesis. Aggregated tau,
but not monomeric tau, inhibited anterograde fast axonal trans-
port. This inhibition requires a small stretch containing amino
acids from the N-terminal region on tau, a phosphatase-activation
domain. The molecular chaperone heat-shock protein 70 (Hsp
70) clearly affects tau oligomers formation and stability, as inves-
tigated in the squid axoplasm. Hsp 70 preferentially bound to
tau oligomers over filaments and prevented anterograde axonal
transport inhibition observed with a mixture of both forms of
aggregated tau (22).
Tau aggregates comprise abnormally hyperphosphorylated and
misfolded tau. Research has traditionally focused on understand-
ing how hyperphosphorylated and aggregated tau mediates dys-
function and toxicity in tauopathies. Recent findings inDrosophila
and rodent models of tauopathy suggest that large insoluble
aggregates such as tau filaments and tangles may not be the key
toxic species in these diseases (23). Thus, some investigators have
shifted their focus to study pre-filament tau species such as tau
oligomers and hyperphosphorylated tau monomers. Interestingly,
tau oligomers can exist in a variety of states including hyper-
phosphorylated and unphosphorylated forms, which can be both
soluble and insoluble. It remains to be determined which of these
oligomeric states of tau are causally involved in neurodegener-
ation and which molecule signal the beginning of the forma-
tion of inert/protective filaments. It will be important to better
understand this aspect so that tau-based therapeutic interventions
can target the really toxic tau species.
Another interesting study showed that oligomers of recombi-
nant full-length human tau protein are neurotoxic in vivo after
subcortical stereotaxic injection into mice. Data showed that tau
oligomers impaired memory consolidation, whereas tau fibrils
and monomers did not. In this context it was assumed that tau
oligomers can affects synaptic transmission. Thus, synaptic dys-
function seems to result from the action of tau oligomers, poten-
tially reducing the activity of the synaptic vesicle-associated pro-
teins synaptophysin (24). Some studies identify tau oligomers as
an acutely toxic tau species in vivo, and suggest that tau oligomers
induce neurodegeneration by affecting mitochondrial and synap-
tic function, both of which are early hallmarks in AD and other
tauopathies (25). These results open new avenues for neuropro-
tective intervention strategies for tauopathies by targeting tau
oligomers.
OLIGOMERS AND THEIR USEFULNESS FOR MONITORING AD
As mentioned above, tau oligomers are one of the neuropatho-
logical hallmarks of AD and other tauopathies. Regarding NFT
accumulation in AD, there is evidence showing that progressive
neuronal loss and cognitive impairment correlates with the accu-
mulation of soluble species of tau in NFTs in AD mouse models
(26). This etiopathological feature has become the target for poten-
tial treatments for AD, diagnosis and monitoring evolution of the
disease. On this last point, some diagnostic biomarkers for AD
based on tau have been developed: (1) biomarkers in cerebrospinal
fluid (CSF) and (2) biomarkers in platelet tau (3). Since in the CSF
significant exchange of substances with a varied neural environ-
ment appears to occur, tau variants are released to the fluid. In this
context, one of the most reliable biomarkers reported was based
on the ratio between normal tau and hyperphosphorylated tau (P-
tau) in the CSF (27). This evaluation about tau and P-tau allows
a better correlation with the later stages of synaptic dysfunction
and early neurodegeneration (27, 28). Furthermore, the second
biomarker is based on the detection of tau in blood platelets (15,
29). Alterations in platelets from AD patients, including modifi-
cations in platelets β-amyloid Precursor Protein (APP) have been
described previously (30) and APP evaluations have been pos-
tulated as a potential biomarker for AD (31). Considering that
information we focused our efforts in analyses of platelets tau pro-
tein. The innovative method was developed in our laboratory and
is based upon the difference between the ratio of molecular species
of high molecular weight tau (multimeric) versus low molecu-
lar weight (monomeric). In western blot experiments performed
with platelet protein extracts obtained from peripheral blood from
healthy subjects and patients with AD, it was observed that the lat-
ter had tau immunoreactive bands migrating at molecular weights
much higher than expected by electrophoresis under denaturing
and reducing conditions (SDS-PAGE) (15). These high molecular
weight forms of tau (tau HMW) could be attributed to oligomeric
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forms of the protein, which are increased in AD patients as com-
pared to healthy elderly subjects (Figure 1). Therefore, platelets
tau has been postulated as a biomarker for AD (29). Different tau
species with variable stages of aggregation are visualized in the
electrophoretic patterns. Subsequent studies by Farias et al. (15),
have shown that there is a close correlation between the degree of
platelet tau modification and level of cognitive impairment, which
was measured using neuropsychological tests in patients with AD
[for more detailed information about these biomarkers see Ref.
(3)]. Moreover, correlations between HMWtau/LMWtau ratio and
brain neuroimaging have been observed. This ratio, controlled for
age and education, significantly correlated with a clusters of 717
voxels in the right parahippocampal cortex with peak at Talairach
coordinates 16,−10,−23 (unpublished observations).
TAU AS A THERAPEUTIC TARGET FOR ANTI-ALZHEIMER
DRUGS
Since tau has been recognized as an important actor in neu-
rodegenerative diseases, many molecules that act on tau pathol-
ogy have been investigated as potential vectors for therapeutic
approaches for AD, but also for other tauopathies such as PSP or
CBD. One of the molecules that have attracted much attention
is the phenothiazine methylthioninium chloride, better known
as methylene blue (MB). MB has a very interesting property
as an aggregation inhibitor for proteins that adopt beta sheet
conformation (32).
Rember™ is the trade name of MB, and a Phase II study ran-
domizing 321 mild to moderate AD patients with placebo or three
different doses of Rember™ was presented in 2008 at the Inter-
national Conference on AD in Chicago. Treatment effects of four
points were described on ADAS-Cog on the treatment group as
compared to placebo subjects, and also conservation on the cere-
bral blood flow and brain glucose used in SPECT and FDG-PET
scans (33). However, as today, the lack of peer reviewed publi-
cations on this compound affect the reliability of the results. In
animal models, the effects of MB on cognition appears not to be
related to a reduction on NFTs but to a decrease in soluble tau
levels (34) (Figure 2).
Other groups have focused their efforts on investigating tau
kinases inhibitors (16) or tau phosphatase activators (17), as an
indirect manner to halt tau hyperphosphorylation, recognized as
leading to pathological aggregation of the protein. However, diffi-
culties in finding specific inhibitors/activators with adequate safety
profiles have impacted in the lack of new drugs in this area (32,
35). A possible way to decrease adverse effects of tau kinase inhi-
bition might be the use of relatively broad specificity, low power
compounds (36).
Davunetide is an eight aminoacids peptide that can be adminis-
tered intranasally or intravenously and has been described as a tau
hyperphosphorylation inhibitor as well as an inhibitor of caspase
3 activation (37). Davunetide has been successfully evaluated in
a series of in vitro and in vivo models (38) for neurodegenerative
diseases that include AD, PSP, and schizophrenia (38, 39).
An example of “non-traditional” approaches to tau aggregation
regulation includes chaperones modulation. Hsp 70 chaperones
assist protein-folding processes and are found up-regulated in sev-
eral tumors, but also in neurodegenerative diseases such as Pick’s
FIGURE 1 | Representative immunoblots of platelet tau with tau-5
antibody. High molecular weight tau bands (about 80 kDa) can be
appreciated, with greater immunoreactivity in patients with Alzheimer’s
disease (AD) compared with control subjects (C). Subsequent
densitometric analysis allows obtaining the relationship between HMWtau
versus LMWtau.
disease,AD,and other tauopathies. Deregulation in Hsp 70 chaper-
ones appears to be implicated in the processes of tau aggregation,
so compounds that bind Hsp 70 chaperones are under investi-
gation as possible treatment compounds for neurodegenerative
diseases, since there is evidence that Hsp 70 inhibition leads to
tau ubiquitination and clearance through ubiquitin-proteasome
system (40).
There are some natural compounds that are able to inhibit
tau aggregation and possibly, make an impact in neurodegener-
ative diseases. Shilajit is a natural phytocomplex that has been
found in the Himalayan Mountains between India and Nepal and
also in the Tibet and Afghanistan and has been used in ayurvedic
medicine for centuries as a rejuvenating compound. Our labora-
tory has worked with the Andean Compound (or Andean shilajit ),
a natural compound that can be found in Andean Mountains.
Andean shilajit is generated by a long-term degradation of cer-
tain plants by microorganisms, mostly fungi and is rich in Fulvic
Acid (FA) and humic substances among others (Figure 2). This
natural endemic phytocomplex, resulting from fossilized plants
degradation through the years, was discovered in 2008 in the
North of Chile and was named Andean Compound (41). In vitro
assays and cell culture data show that Andean Compound and
FA strongly interferes with tau aggregation, and interestingly an
increase in neurites outgrowth has been observed in neural cell
cultures exposed to this natural compound (42). In addition, a
placebo-controlled pilot clinical study suggests that consumption
of a nutraceutical formulation of Andean Compound plus B com-
plex vitamins may produce stabilization of cognitive function in
AD patients at a 24-weeks as determined with Global deterioration
scale (GDS) and Neuropsychiatric inventory (NPI) measurements
(42) (Figure 2). On the other hand the same shilajit – based
compound has a very good safety profile when tested on healthy
population (unpublished data).
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FIGURE 2 | Schematic representation on the changes in tau
leading to pathological conditions, formation of neurofibrillary
tangles, and some molecules that exert their actions on
polymeric forms of pathological tau and that appear to prevent
polymers formation and possible disassembly of these
filaments.
CONCLUDING REMARKS
Currently, we do not know the exact cause of synaptic dys-
function and neurodegeneration in AD, however, in recent years
it has become increasingly clear the importance of tau protein
and its post-translational modifications in the pathophysiological
processes of AD and other tauopathies.
In this context, determination of different forms of tau protein
in brain, CSF (43) and also in blood (44) and peripheral cells (15)
has been postulated as a powerful tool for detection and moni-
toring of the disease in different stages and there is clear evidence
of a profile of tau and other biomarkers modifications during AD
progression (45, 46). The presence of tau modifications in periph-
eral cells also points to the inference that AD may be a systemic
disease not only confined to nervous tissue. But currently we do
not have any information on the functional impact – if any – of
oligomeric tau forms in peripheral cells. The latest criteria of AD
consider tau-based biomarkers as reliable indicators of neuronal
injury processes (47), but as of today there is not a widely available
marker of tau modification for clinical use. Hopefully in the near
future we will refine techniques for non-invasive assessment of
tau. Thereon, are extremely interesting attempts to generate PET
markers for tau deposition in brain (48, 49) and we already have
promising data regarding measurement of different forms of tau
in blood cells (15, 29).
On the other hand, in the absence of positive clinical results
in studies with beta amyloid targeted therapies, the need to
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evaluate therapies that can act on post-translational changes of
tau protein has become evident. Particular interest has been
paid to therapies that may modulate levels of phosphorylation
and oligomerization of tau, whether by direct action on tau or
by acting on other related proteins like kinases or heat-shock
proteins.
Unfortunately we still need information from large multicen-
ter studies about the usefulness of tau-focused therapies, however,
this is a promising field that has attracted the efforts of multiple
investigators, so we expect that new and exciting discoveries are
right around the corner.
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